BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 10529069)

  • 1. Predictors of an acute antidepressant response to fluoxetine and sertraline.
    Flament MF; Lane RM; Zhu R; Ying Z
    Int Clin Psychopharmacol; 1999 Sep; 14(5):259-75. PubMed ID: 10529069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
    Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
    Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline.
    Brady KT; Clary CM
    Compr Psychiatry; 2003; 44(5):360-9. PubMed ID: 14505296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine.
    Tollefson GD; Sayler ME
    Depress Anxiety; 1996-1997; 4(6):294-311. PubMed ID: 9166658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
    Sandor P; Baker B; Irvine J; Dorian P; McKessok D; Mendlowitz S
    Depress Anxiety; 1998; 7(2):69-72. PubMed ID: 9614594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major depressive subtypes and treatment response.
    Fava M; Uebelacker LA; Alpert JE; Nierenberg AA; Pava JA; Rosenbaum JF
    Biol Psychiatry; 1997 Oct; 42(7):568-76. PubMed ID: 9376453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
    Marchesi C; Ceccherininelli A; Rossi A; Maggini C
    Pharmacopsychiatry; 1998 Nov; 31(6):216-21. PubMed ID: 9930635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study.
    Baca E; González de Chávez M; García-Toro M; Pérez-Arnau F; Porras-Chavarino A
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):493-500. PubMed ID: 12691786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia.
    Mendels J; Kiev A; Fabre LF
    Depress Anxiety; 1999; 9(2):54-60. PubMed ID: 10207659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
    Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
    J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fluoxetine on fine motor performance in dysthymia: an 8-week, nonrandomized, open-label study.
    Schrijvers D; Maas YJ; Sabbe BG
    Clin Ther; 2009 Jan; 31(1):123-9. PubMed ID: 19243713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder.
    Steiner M; Allgulander C; Ravindran A; Kosar H; Burt T; Austin C
    Hum Psychopharmacol; 2005 Jan; 20(1):3-13. PubMed ID: 15551351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders.
    Baca E; Garcia-Garcia M; Porras-Chavarino A
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):57-65. PubMed ID: 14687858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.